Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the rejection of pluripotent stem cell (PSC)-derived products in allogeneic recipients. Disruption of the Beta-2 Microglobulin (B2M) gene eliminates surface expression of all class I molecules, but leaves the cells vulnerable to lysis by natural killer (NK) cells. Here we show that this 'missing-self' response can be prevented by forced expression of minimally polymorphic HLA-E molecules. We use adeno-associated virus (AAV)-mediated gene editing to knock in HLA-E genes at the B2M locus in human PSCs in a manner that confers inducible, regulated, surface expression of HLA-E single-chain dimers (fused to B2M) or trimers (fused to B2M and a peptide antigen), without surface expression of HLA-A, B or C. These HLA-engineered PSCs and their differentiated derivatives are not recognized as allogeneic by CD8 + T cells, do not bind anti-HLA antibodies and are resistant to NK-mediated lysis. Our approach provides a potential source of universal donor cells for applications where the differentiated derivatives lack HLA class II expression.
A r t i c l e s Cellular products derived from human pluripotent stem cells (PSCs) have the potential to treat many human diseases, but their clinical use is limited by the host rejection of transplanted cells owing to expression of the highly polymorphic human leukocyte antigen (HLA) genes. Various solutions have been proposed for this allogeneic rejection problem, including HLA-typed PSC banks 1 , or the derivation of induced PSCs from each patient 2 , but these approaches require that multiple cell lines be derived 3 , differentiated into therapeutic products and approved for human administration. The development of a single PSC line that can avoid allogeneic rejection would greatly reduce the time and expense required to advance cellular therapies to the clinic.
HLA class I molecules are expressed on most cells and play a central role in allogeneic rejection through their presentation of peptide antigens to CD8 + T cells 4 . Beta-2 Microglobulin (B2M) is a nonpolymorphic gene that encodes a common protein subunit required for surface expression of all polymorphic HLA class I heavy chains 5 . Our group 6 and others [7] [8] [9] have created B2M −/− human PSCs in order to eliminate class I surface expression and prevent the stimulation of allogeneic CD8 + T cells. However, a major limitation of this simple engineering strategy is that HLA class I-negative cells are lysed by natural killer (NK) cells through the missing-self response 10, 11 . In mice, host NK cells eliminate transplanted B2m −/− donor cells 10 , and a similar phenomenon occurs in vitro with HLA class-I-negative human leukemic lines 12 . This NK cell-dependent lysis is normally inhibited through interactions with class I molecules 13 , including the minimally polymorphic HLA-E protein [14] [15] [16] , which presents peptides derived from the signal sequences of other HLA class I molecules 17 , and is a ligand for the inhibitory CD94/NGK2A complex expressed on the majority of NK cells 14, 15, 18 . Like other HLA class I molecules, HLA-E forms a heterodimer with a B2M subunit so it is not expressed on the surface of B2M −/− cells. We surmised that B2M −/− cells could be engineered to express HLA-E as a single-chain protein fused to B2M, and thereby create cells that express HLA-E as their only surface HLA class I molecule.
Here we use recombinant adeno-associated virus (rAAV)-mediated gene editing to create such PSCs. rAAV vectors deliver single-stranded linear DNA genomes that efficiently recombine with homologous chromosomal sequences in up to 1% of infected human cells without the use of potentially genotoxic nucleases 19, 20 , including human PSCs [21] [22] [23] . We show that single-chain HLA-E molecules prevent the NK-mediated lysis of B2M −/− cells without stimulating allogeneic T cells, addressing a major problem in the creation of universal donor cells for regenerative medicine applications.
RESULTS

Generation of HLA-E knock-in cells at the B2M locus
Two types of HLA-E single-chain fusion constructs were designed for our experiments (Fig. 1a) . The HLA-E single-chain dimer consists of an HLA-E heavy chain covalently fused to B2M through a flexible (G 4 S) 4 linker, such that it can bind a normal repertoire of peptides for antigen presentation. The HLA-E single-chain trimer contains an additional (G 4 S) 3 linker fused to a peptide derived from the signal sequence of HLA-G (another HLA class I molecule), which is a nonpolymorphic peptide normally presented by HLA-E that inhibits NK cell-dependent lysis through its binding to CD94/NGK2A 15 . rAAV gene editing vectors were designed to introduce HLA-E constructs at the B2M locus, such that an HLA-E single-chain dimer or trimer would be expressed under the control of the B2M promoter
HlA-e-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells (Fig. 1b) . In our strategy, the first allele of B2M is edited with a vector that inserts a loxP-flanked (floxed) HyTK fusion gene encoding hygromycin resistance and thymidine kinase at exon 1 to create a null allele (AAV-B2M-HyTK), and the second B2M allele is then edited to express HLA-E. Vector AAV-B2M-Edimer inserts an HLA-E heavy chain reading frame at exon 3 of B2M for HLA-E single-chain dimer expression, and AAV-B2M-Etrimer inserts a full HLA-E single-chain trimer gene at exon 1 (including a codon-optimized, wobbled B2M reading frame). Both the dimer and trimer vectors also contain floxed Neo expression cassettes for G418 selection. A second B2M knockout vector was also constructed that inserts a floxed TKNeo fusion gene at exon 1 in order to create B2M −/− control cells (AAV-B2M-TKN).
Human Elf-1 embryonic stem cells (ESCs) were serially infected with these rAAV vectors, and 7-43% of selected clones were accurately edited, based on screening by PCR with primers in the transgene and outside of the homology arms ( Fig. 1c and Table 1 ). PCR-positive clones infected with AAV-B2M-Edimer were further screened by Southern blot analysis to determine which allele was edited, with 6 of 13 clones edited at the second B2M allele ( Table 1) . Three of these B2M −/Edimer(pre-Cre) clones were subsequently infected with a non-integrating foamy virus vector to transiently express Cre, as described 6 , and 42-46% of ganciclovir-resistant clones had lost both the HyTK and Neo cassettes to produce a B2M −/Edimer genotype. To create cells with a B2M −/Etrimer genotype, we used flow cytometry to sort a polyclonal population of G418-resistant cells infected with AAV-B2M-Etrimer for the absence HLA-A,B,C expression, which ensured that the second allele had been edited. Southern blot analyses confirmed that accurate editing occurred ( Fig. 1c and Supplementary  Fig. 1a ) and reprobing showed that none of the edited clones had random integrants (data not shown). B2M −/Edimer clones c1 and c2 and B2M −/Etrimer clones c5 and c6 had normal karyotypes (data not shown) and were selected for subsequent studies.
Generation of B2M −/− control cells
We attempted to establish B2M −/− control cells by infecting B2M +/− cells with the second knockout vector AAV-B2M-TKN ( Fig. 1) , but we Supplementary Fig. 1a ).
consistently obtained G418-resistant cells that had been retargeted at the allele previously edited by the AAV-B2M-HyTK vector, in contrast to the approximately 50:50 allele ratio obtained with the AAV-B2M-Edimer vector ( Table 1 ). In addition, the rare G418-resistant colonies that appeared to be targeted at the second allele by PCR were mixed populations when examined by flow cytometry, and upon further subcloning, we were unable to obtain pure populations that lacked B2M expression and maintained a normal karyotype ( Supplementary Fig. 1b ).
Ultimately, we were able to isolate two pure B2M −/− clones by repeated subcloning and flow cytometry screening of two independently edited cell populations ( Supplementary Fig. 1c ), but in both cases the clones had abnormal karyotypes ( Supplementary Fig. 1d ).
These results suggested that euploid B2M −/− Elf-1 ESCs grow poorly, which was surprising given that we had previously generated euploid H1 ESCs with both B2M alleles edited by the nearly identical knockout vectors AAV-B2M-EHyTKpA and AAV-B2M-ETKNpA ( Table 1) 6 . This was not a unique property of Elf-1 cells, since we also failed to generate B2M −/− H1 ESCs with the newer vectors ( Fig. 1 and Table 1 ). Another possible explanation was that the identical TK sequences present in both vectors were preferentially promoting recombination at the previously edited allele, but when the TK reading frame was wobbled to reduce homology, we were still unable to isolate ESCs edited at both alleles ( Table 1) . These failures led us to re-examine the euploid B2M −/− H1 ESCs edited with our original vectors, and we found that low levels of class I proteins could be detected by flow cytometry after interferon (IFN)-γ induction of HLA gene expression ( Supplementary  Fig. 2a ), suggesting that these edited alleles were leaky. This was confirmed by RT-PCR analysis, which detected an mRNA from the edited alleles generated by read-through transcription beyond the pA signal into an open reading frame with an ATG initiation codon in a loxP site and a novel signal sequence in-frame with downstream B2M sequences ( Supplementary Fig. 2b ). This leakiness was not a feature of alleles edited by the newer vectors AAV-B2M-HyTK and AAV-B2M-TKN, which contained additional stop codons downstream from the pA signal to block B2M protein production ( Supplementary Fig. 2C ). Taken together, these results suggest that a complete lack of B2M expression slows the growth of normal, euploid ESCs. Importantly, this was not a feature of ESCs that uniquely expressed HLA-E single-chain dimers or trimers, which grew well and had normal karyotypes.
HLA expression in edited cells
Our editing strategy produces HLA-E single-chain genes that are expressed from the B2M promoter, so they should be regulated appropriately in response to cytokines. Undifferentiated ESCs with the B2M genotypes shown in Figure 1 were cultured with and without IFN-γ, and the levels of cell surface HLA class I molecules were determined by flow cytometry (Fig. 2) . In the absence of IFN-γ, B2M +/+ ESCs expressed nearly undetectable amounts of both HLA-E and polymorphic class I molecules (HLA-A, B and C), all of which were upregulated significantly in the presence of IFN-γ. In contrast, B2M −/− ESCs had no surface expression of HLA class I molecules, even in the presence of IFN-γ, confirming that these cells have a complete knockout of B2M (although they acquired an abnormal tetraploid karyotype).
B2M −/Edimer(preCre) cells expressed low levels of HLA-E upon IFN-γ induction, which explains why these clones could be easily obtained by gene editing, even though they did not express HLA-A, B or C molecules. A similar pattern was observed with B2M −/Edimer cells after Cre-mediated removal of the Neo cassette, but with higher HLA-E single-chain dimer expression. B2M −/Etrimer cells were distinct in that they also expressed HLA-E without IFN-γ induction, as observed for two independent clones, as well as higher levels upon IFN-γ induction. It is possible that in the absence of IFN-γ, the wild-type (WT) HLA-E and HLA-E dimer molecules were not effectively loaded with peptides, which reduces surface expression levels. Both B2M −/Edimer and B2M −/Etrimer cells expressed higher than normal levels of HLA-E, reflecting the fact that all the proteins expressed from one edited B2M allele were HLA-E single-chain molecules, in contrast to WT B2M proteins that are shared by all types of class I heavy chains. To assess whether expression of HLA-E as the only HLA class I surface molecule influenced differentiation, we derived retinal pigmented epithelium (RPE) cells from B2M −/Edimer ESCs in vitro, and the results were similar to those obtained with B2M +/+ ESCs. Both lines had efficient RPE differentiation, as shown by their cuboidal morphology, and staining for PMEL and MITF (Supplementary Fig. 3 ).
HLA-E single-chain expression prevents NK-mediated lysis
Undifferentiated ESCs have limited immunogenicity and do not induce NK-mediated lysis 24 , so we differentiated ESCs into CD45 + hematopoietic derivatives ( Fig. 3a) before characterizing their immune reactivity. Flow cytometry showed there were >89% CD45 + hematopoietic cells on day 38 in all edited cell lines except A r t i c l e s B2M −/− cells ( Fig. 3b and Supplementary Fig. 4a) , where the total yield of suspension culture cells (containing CD45 + hematopoietic cells) was ~10 times lower ( Supplementary Fig. 4b ), presumably because of impaired differentiation in these karyotypically abnormal lines. HLA class I expression in ESC-derived CD45 + cells was similar to that observed in undifferentiated ESCs, with IFN-γ-inducible HLA-E expression and no other surface class I molecules in B2M −/Edimer and B2M −/Etrimer cells (Fig. 3c ). One notable difference was that the B2M −/Edimer(preCre) cells had virtually no detectable HLA-E expression, so for some experiments they were used as class-I-negative controls, since B2M −/− CD45 + cells could not be produced in adequate numbers.
HLA-E binds to both the inhibiting and activating receptors NKG2A and NKG2C, respectively 25 , but NKG2A is expressed in most human NK cells 18 , so we expected that the overall effect of HLA-E should be inhibitory. Allogeneic peripheral blood CD56 + NK cells isolated from normal donors were incubated with 51 Cr-labeled ESC-derived CD45 + cells, and lysis was measured in chromium release assays. A typical NK donor with 83.7% NKG2A + cells and 8.1% NKG2C + cells (Fig. 3d) showed increased lysis of class-I-negative B2M −/Edimer(preCre) CD45 + cells as compared to class I-expressing cells, confirming that the missing-self response observed in mice is also important for human hematopoietic cells (Fig. 3e) . This increased lysis was completely reversed by expression of HLA-E single-chain molecules in B2M − /Edimer and B2M −/Etrimer CD45 + cells, and at lower NK/CD45 cell ratios, HLA-E single-chain expression reduced lysis to below that of B2M +/+ CD45 + cells, perhaps due to their higher than normal HLA-E levels, or a lack of interactions with activating Killer-cell Immunoglobulin-like Receptors (KIRs). Blocking antibodies against HLA-E or NKG2A increased the lysis of B2M −/Edimer cells ~2.5 fold, confirming that the HLA-E-NKG2A interaction was responsible ( Fig. 3f) . NK cells from a donor with unusually low NKG2A expression (49.86% NKG2A + , 3.66% NKG2C + ; Supplementary Fig. 4c ) also preferentially lysed class-I-negative ESC-derived CD45 + cells, and this was partly reversed by HLA-E expression in B2M −/Edimer cells (Supplementary Fig. 4d) . Control experiments confirmed that both B2M −/− and B2M −/Edimer(pre-Cre) CD45 + cells were lysed at equivalent levels by NK cells, and that HLA-E expression also prevented lysis by NK cells grown at lower interleukin (IL)-2 concentrations (Supplementary Fig. 4e,f) . To provide an in vivo proof of concept, we monitored the survival of luciferase-expressing ESC-derived CD45 + cells and teratomas in immunodeficient mice and showed that HLA-E expression improved survival in mice that also received NK-92 cells, an NK cell line that expresses NKG2A 26, 27 (Fig. 3g,h and Supplementary Fig. 4g,h) . Taken together, these experiments demonstrate that HLA-E single-chain expression prevents NK-mediated lysis in otherwise HLA class-I-negative cells.
HLA-E single-chain-expressing cells are not recognized as allogeneic We used both in vitro and in vivo models to determine if allogeneic T cells recognize and respond to B2M −/Edimer and B2M −/Etrimer cells (Fig. 4a) . Normal, human CD8 + T cells were first cocultured with embryoid bodies derived from B2M +/+ Elf-1 ESCs, to enrich for T cells that recognize Elf-1 class I molecules. Embryoid bodies contain several types of cells and express high levels of HLA class I molecules, but not HLA class II (e.g., HLA-DR; Supplementary Fig. 5a ). The costimulatory molecules CD40 and CD54 were also present on embryoid body cells, but not CD86, CD80, CD83 or CD275 ( Supplementary  Fig. 5b) . These embryoid-body-primed T cells were then incubated with 51 Cr-labeled ESC-derived CD45 + cells in chromium release assays to detect T-cell-mediated cytotoxicity. The CD45 + cells robustly expressed CD40, CD54 and CD86 costimulatory molecules (Supplementary Fig. 5c ). While embryoid body-primed T cells efficiently lysed B2M +/+ CD45 + cells, they did not kill B2M −/Edimer(preCre) , B2M −/Edimer or B2M −/Etrimer CD45 + cells (Fig. 4b) , and a similar protection from lysis was observed for ESC-derived RPE cells expressing HLA-E (Fig. 4c) , demonstrating both that cytotoxic T-cell responses can be prevented by eliminating surface expression of polymorphic class I molecules, and that non-polymorphic HLA-E single-chain dimers and trimers do not stimulate lysis. These experiments also show . P values were calculated using the oneway ANOVA followed by Tukey HSD test; asterisks indicate statistical significant differences in regard to no antibody controls. (g) Luciferase imaging of five representative mice containing ESC-derived CD45 + cells of B2M −/Edimer(pre-Cre) (serves as class-I-negative control) or B2M −/Etrimer genotypes, some of which also received NK-92 cells (− or + labels in the right panel). Results are shown for the same mice before NK-92 injection (day 1) and 1 d afterwards (day 2). (h) Quantification of luciferase-expressing CD45 + cell levels in mice treated as in g. The change in luminescence between day 1 (pre NK-92 cell injection) and day 2 or day 1 and day 4 (1 or 3 d after NK-92 cell injection) was measured for individual mice and divided by the average of control mice that did not receive NK-92 cells (n = 3 for both B2M −/Etrimer and B2M −/Edimer(pre-Cre) control groups). Horizontal black bars indicate the mean for each group. P values were calculated using the unpaired Student's t test. For all panels, **P < 0.01 and *P < 0.05.
A r t i c l e s that indirect HLA class I antigen presentation as modeled by priming CD8 + T cells with WT embryoid bodies does not stimulate responses against B2M −/Edimer and B2M −/Etrimer cells, which contain intracellular polymorphic heavy chains.
In vivo responses were examined by growing luciferase-expressing B2M +/+ and B2M −/Etrimer ESC-derived teratomas in immunodeficient mice, and transplanting primed allogeneic CD8 + T cells labeled with VivoTrack 680 (examples in Fig. 4d ). Serial luciferase measurements showed that B2M −/Etrimer teratomas grew more than their B2M +/+ counterparts in five of six mice after CD8 + cell infusion ( Fig. 4e and  Supplementary Fig. 6a ), but this did not occur in the absence of CD8 + cells (Fig. 4f) . Similar results were obtained in separate experiments with three different CD8 + T cell donors (Supplementary Fig. 6b) . CD8 + cells also preferentially localized to B2M +/+ teratomas as measured by in vivo tracking (Fig. 4g) . Histological examination demonstrated multiple areas of necrosis in the B2M +/+ teratomas as well as the presence of human CD8 + cells at higher levels than found in B2M −/Etrimer teratomas ( Fig. 4h and Supplementary Fig. 6c) .
We also examined possible B-cell responses against ESC-derived CD45 + cells by performing a complement-dependent cytotoxicity (CDC) assay with human serum samples containing defined anti-HLA antibodies ( Table 2) . Cytotoxicity was detected when B2M +/+ cells were exposed to 14 of 16 sera samples with antibodies against Elf-1 HLA-A or B alleles (A*11, A*24, B*35 and B*55), but not after exposure to 16 samples with antibodies against other HLA-A or B alleles, demonstrating the accuracy of the assay. No cytotoxicity was observed for B2M −/Edimer(pre-Cre) , B2M −/Edimer or B2M −/Etrimer cells, except for one single sample reacting against B2M −/Etrimer c6, which could reflect contaminating antibodies against non-HLA class I antigens, including possible class II alleles that may be expressed in some CD45 + cells.
DISCUSSION
In this report we show that HLA-E single-chain dimer and trimer expression in human cells lacking polymorphic HLA class I surface molecules can prevent the missing-self response. Most human NK cells express NKG2A 18 , an inhibitory receptor that binds HLA-E, and this interaction was enough to reduce NK-mediated lysis of CD45 + cells that uniquely expressed HLA-E to a level below that of WT cells, and to protect cells from NK-92 cell-mediated lysis in vivo. This level of host NK cell population inhibition may also be adequate to protect transplanted cells in clinical trials, given that cumulative NK signaling can dictate the outcome 28 , and in mice NK cells can be tolerized to B2m −/− cells over time 29 . If necessary, the subset of host NK cells that are NKG2A-negative could be inhibited with additional gene editing steps, such as expressing single-chain HLA-G proteins 13, 30 and/or other class I molecules targeting inhibitory KIR 31 or other NK receptors 25 , especially in recipients with fewer NKG2A + NK cells.
We were surprised that B2M −/− human ESCs completely lacking surface HLA class I proteins grew poorly and failed to differentiate robustly into CD45 + cells, given the relative health of B2m −/− mice 32, 33 . Other groups have described B2M knockouts in human cells [7] [8] [9] 34 , with at least one report showing that the editing frequencies were lower than expected in normal T cells as compared to HEK293 cells 34 . These findings suggest that B2M-edited cells should be carefully screened for low level or inducible class I surface expression and/or compensatory mutations. The two independent B2M −/− lines that we eventually isolated by repeated subcloning had common cytogenetic abnormalities (tetraploidy, add20(q13), −15 and −22) that may have improved their survival. While the basis for the poor growth of B2M −/− human cells is not understood, it is not a feature of cells that express HLA-E as their sole class I surface 
protein, which grew normally and produced hematopoietic cells and RPE cells as efficiently as WT cells. B2M −/Edimer and B2M −/Etrimer ESCs and their differentiated derivatives were not lysed by CD8 + T cells, and they were not recognized by human anti-HLA antibodies. Thus these cells were not only resistant to NK-mediated lysis, but they were not recognized as allogeneic, and their expression of single-chain HLA-E molecules was not immunogenic. These in vitro findings were confirmed by in vivo studies showing that allogeneic CD8 + cells invaded B2M +/+ teratomas more than B2M −/Etrimer teratomas, reducing their growth rate and producing necrosis. Our results support the use of HLA-E-expressing PSCs as a source of first-generation, universal donor cells, at least in applications where the transplanted cell type does not express HLA class II molecules. Additional engineering steps could be used to prevent class II expression, such as knocking out the genes responsible for bare lymphocyte syndrome 35 . While HLA-engineering should minimize the rejection of many types of PSC-derived cell products, especially relevant clinical applications include hematopoietic cell transplantation where HLA mismatches profoundly affect engraftment, and autoimmune or genetic diseases where the presentation of autoantigens and neoantigens would otherwise cause rejection.
Reduced HLA expression also raises specific safety concerns. Class I-deficient mice and humans are not tumor-prone 36, 37 , but class I peptide presentation may contribute toward the elimination of malignant cells formed by other mechanisms, and it plays a role in clearing infections. The HLA-E dimer molecule could provide some protection in these settings, since HLA-E can present pathogen-specific peptides that are recognized by cytotoxic T cells 38, 39 , and possibly tumor-specific peptides as well 40 . HLA-independent mechanisms should also limit infections based on the partial immunity of class I-deficient humans 37 and mice [41] [42] [43] . In addition, many regenerative medicine applications will involve the treatment of recipients with normal immune systems, delivery to internal sites sequestered from pathogens and the transplantation of terminally differentiated and possibly irradiated PSC-derived cells that are resistant to transformation. Ultimately, the safety of these cell products may be enhanced by the inclusion of suicide genes such as the TK gene used in our editing steps, and the extensive pre-clinical testing that the use of a single universal donor cell line allows, which may not be practical when characterizing cellular products derived from multiple autologous induced PSCs or HLA-typed PSC banks.
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